GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011. Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md.
For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully human antibodies. In this position, he held responsibilities for a variety of areas, including corporate development, technical operations, corporate legal, human resources, and public and investor relations. In 1999, Lemus led the effort to take the company public, successfully completing Germany's first-ever biotech initial public offering. For the next decade thereafter, he played a central role in helping grow the company into one of Europe's leading life science companies.
"I'm very pleased to become part of the Sigma-Tau growth story going forward as its new vice president of finance," commented Lemus. "Moreover, Sigma-Tau's considerable expertise in rare diseases will continue to play a decisive role in propelling the company's high rate of growth and expansion over the coming years."
Prior to his role at MorphoSys AG, Lemus was a controller and operations manager at Hoffmann-La Roche, and preceding this position, he served as the treasurer of the Lindt Chocolate Company.
"As a leader in the development and commercialization of medicines for rare diseases, we have undergone tremendous growth in the past few years," said Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc. "In looking to the future, it's imperative we have talented people like Dave to help Sigma-Tau continue to bring innovation to the field of rare diseases. We're very pleased to welcome him to the team."
Sigma-Tau Pharmaceuticals, In
|SOURCE Sigma-Tau Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved